🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

8 results for “elranatamab” Clear

  1. Bortezomib STADA 2,5 mg/ml Injektionslösung, Dexamethason 0,5 mg JENAPHARM®, Empliciti 400 mg powder for concentrate for solution for infusion., Kyprolis 60 mg powder for solution for infusion, Privigen 100 mg/ml solution for infusion, Privigen 100 mg/ml solution for infusion, Imnovid 1 mg hard capsules, -, Nodexon 20 mg tabletes, Imnovid 3 mg hard capsules, Imnovid 4 mg hard capsules, Imnovid 2 mg hard capsules, Nodexon 20 mg tabletės, ELRANATAMAB, Dexamethason 4 mg JENAPHARM®

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Relapsed/Refractory Multiple Myeloma

    phase 3 small molecule active

    1 trial
  2. ELRANATAMAB

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Multiple myeloma

    phase 3 small molecule active

    1 trial
  3. Neofordex 40 mg tablets, Imnovid 4 mg hard capsules, Imnovid 1 mg hard capsules, DARZALEX 1800 mg solution for injection, Imnovid 2 mg hard capsules, Privigen 100 mg/ml solution for infusion, ELRANATAMAB, Imnovid 3 mg hard capsules

    Pfizer Ireland Pharmaceuticals Unlimited Company

    MULTIPLE MYELOMA

    phase 3 small molecule active

    1 trial
  4. Zelvina 15 mg hard capsules, Zelvina 5 mg hard capsules, ELRANATAMAB, Zelvina 10 mg hard capsules, Privigen 100 mg/ml solution for infusion

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Multiple Myeloma

    phase 3 small molecule active

    1 trial
  5. Zelvina 25 mg hard capsules, Dexamethasone 0.5mg Tablets, Zelvina 15 mg hard capsules, ELRANATAMAB, Privigen 100 mg/ml solution for infusion, Zelvina 2.5 mg hard capsules, Zelvina 10 mg hard capsules, VELCADE 3.5 mg powder for solution for injection, Nodexon 20 mg tabletid, DARZALEX 1800 mg solution for injection, Nodexon 20 mg tabletės, Nodexon 20 mg tabletes, Nodexon 20 mg tabletės, Dexamethasone 4 mg tablets, Zelvina 5 mg hard capsules

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Multiple myeloma

    phase 3 small molecule active

    1 trial
  6. DEXAMETHASONE, ELRANATAMAB, CC-92480, CC-92480, CC-92480, CC-92480, CC-92480, CC-92480

    Celgene Europe Limited

    Relapsed or Refractory Multiple Myeloma (RRMM)

    phase 2 small molecule active

    1 trial
  7. ELRANATAMAB

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Multiple myeloma

    phase 2 small molecule active

    1 trial
  8. POMALIDOMIDE , ELRANATAMAB, AZD0305, ELRANATAMAB

    AstraZeneca AB

    Multiple Myeloma

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources